Diamyd Medical AB (publ) and JDRF have entered into a fouour-year research and development collaboration including a non-dilutive $5 million award to Diamyd Medical to support its ongoing Phase 3 trial with the precision medicine antigen-specific immunotherapy Diamyd. The grant will be funded under JDRF's Industry Discovery & Development Partnerships program that focuses on commercialization of therapeutics and devices for the treatment, cure, and prevention of type 1 diabetes and its complications.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.82 SEK | -0.67% | -1.17% | +79.91% |
05-16 | Diamyd Medical AB Updates on the Registrational Phase 3 Trial | CI |
04-18 | Diamyd Medical Raises SEK57 Million in Rights Issue | MT |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+79.91% | 111M | |
+10.45% | 115B | |
+12.13% | 106B | |
-6.72% | 24.69B | |
-1.14% | 21.97B | |
-4.97% | 19.27B | |
-12.05% | 17.56B | |
-39.36% | 17.32B | |
+5.39% | 14.03B | |
+33.16% | 12.13B |
- Stock Market
- Equities
- DMYD B Stock
- News Diamyd Medical AB
- Diamyd Medical AB Partners with JDRF to Advance the DIAGNODE-3 Phase 3 Trial in Type 1 Diabetes